Over 1.44 lakh Covid vaccines administered in Delhi on Thursday

By: |
August 20, 2021 6:40 PM

The bulletin issued on Friday showed that 1,06,728 people received their first dose while 38,192 were administered the second dose of Covid vaccine.

Sanjay Singh, CEO of Gennova Biopharmaceuticals, said after establishing the safety of the mRNA-based Covid-19 vaccine candidate HGCO19 in Phase I clinical trial, the company would start Phase II/III clinical trial.Sanjay Singh, CEO of Gennova Biopharmaceuticals, said after establishing the safety of the mRNA-based Covid-19 vaccine candidate HGCO19 in Phase I clinical trial, the company would start Phase II/III clinical trial.

Over 1.44 lakh people were vaccinated against COVID-19 in the national capital on Thursday, according to the Delhi government’s vaccination bulletin.

The bulletin issued on Friday showed that 1,06,728 people received their first dose while 38,192 were administered the second dose of Covid vaccine.

The city has administered 1,21,16,533 Covid vaccines so far, of which 86,86,698 were first doses and 34,29,835 second doses, it showed.

As of Friday morning, the national capital had only two days of vaccine stocks left, the bulletin claimed.

Delhi had a balance stock of 4,07,270 coronavirus vaccines, of which 2,02,280 doses were of Covishield and 2,04,990 of Covaxin.

The national capital has 915 Covid vaccination centres with a capacity of inoculating 1,77,496 beneficiaries per day.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1This World Patient Safety Day, let’s work together to empower our nurses and midwives
2Covid-19: Researchers working on making edible plants like spinach, lettuce as mRNA vaccines; check details
3US OKs new use for Eli Lilly’s COVID-19 treatment